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Abstract
The CHEK2 gene encodes the CHK2 protein, which is kinase involved in DNA repair processes. By activating a lot of cell substrates, it can
regulate the cell cycle, demonstrates suppressive effects, and participates in the senescence and apoptosis processes. Mutations in the
CHEK2 gene are associated with increased risk of numerous cancers. The case described herein is that of a woman with a missense
mutation that results in the substitution of isoleucine for threonine at position 157. This variant of the mutation doubles the risk of papillary
thyroid carcinoma two times and causes up to 9% of these cancer. It is also associated with a two-fold increased risk of cancers of the kidney
(10%), colon (10%), and ovary (10% — G1), a 1.6-fold increased risk of prostate cancer (8% of all of them and 12% of familiar ones), and a 1.5-
-fold increased risk of breast cancer (7%). The screening procedures were initiated in a carrier who revealed papillary thyroid carcinoma.
Genetic screening of the family diagnosed her daughter as the carrier of this mutation. Until now no active cancer disease has been
recognized in the daughter. On the example of the presented case we discuss indications for screening in cases of positive family history.
The group especially predisposed seem to be patients with at least two coexisting carcinomas. Having diagnosed the mutation, it is
necessary to do genetic screening of family members. Continuous oncological observation of the carriers of CHEK 2 mutation is essential.
(Pol J Endocrinol 2010; 61 (5): 502–506)
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Streszczenie
Ludzki gen CHEK2 koduje białko CHK2, będące kinazą efektorową zaangażowaną w naprawę DNA. Aktywując wiele substratów komór-
kowych, bierze udział w regulacji cyklu komórkowego, wykazuje działanie supresyjnie, wpływa również na proces apoptozy i starzenia
się komórek. Mutacje genu CHEK2 są związane z ryzykiem licznych nowotworów. Opisywany przypadek chorej dotyczy mutacji typu
missens, gdzie dochodzi do zamiany izoleucyny na treoninę w pozycji 157. Mutacja ta zwiększa 2-krotnie ryzyko raka brodawkowatego
tarczycy. Predysponuje do występowania 2-krotnie częściej raka nerki (10%), jelita grubego (10%), jajnika (10% — G1), 1,6-krotnie częściej
raka prostaty (8% wszystkich i 12%występujących rodzinnie) oraz 1,5-krotnie częściej raka piersi (7%). Na podstawie diagnostyki
w kierunku predysponowanych nowotworów wykryto u chorej raka brodawkowatego tarczycy. Skrining genetyczny rodziny pozwolił
na wykazanie nosicielstwa tej mutacji u córki pacjentki — dotychczas nie stwierdzono u niej czynnej choroby nowotworowej. Opisywany
przypadek chorej wskazuje na celowość przeprowadzania badań genetycznych w przypadku dodatniego wywiadu rodzinnego w kie-
runku chorób nowotworowych. Szczególnie predysponowaną grupą wydają się być chorzy z co najmniej dwoma współistniejącymi
nowotworami. Wykazanie mutacji nakłada obowiązek badań genetycznych u pozostałych członków rodziny, jak również bezterminowy
nadzór onkologiczny u nosicieli mutacji. (Endokrynol Pol 2010; 61 (5): 502–506)
Słowa kluczowe: gen CHEK2, białko CHK2, mutacja missens CHEK2 (I157T), rak brodawkowaty tarczycy
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Introduction
Human gene CHEK2 encodes CHK2 protein, a protein
kinase engaged in DNA-repair. Activating cell sub-
strates, it regulates the cell cycle and affects apoptosis
and aging of cells [1, 2]. Mutations of the CHEK2 gene
lead to the development of various cancers [1–3]. The
two main groups of mutations of this gene are charac-
terized by either truncation of the encoded protein or
the missense type, with the substitution of one amino
acid into another. The described case refers to the mis-
sense mutation which leads to substitution of isoleu-
cine at position 157 with threonine. CHEK2 mutation
(I157T) doubles the risk of papillary thyroid carcinoma
and causes up to 9% of these cancers [3, 4]. It predis-
poses to twice as frequent incidence of cancers of the
kidney (10%), colon (10%), and low grade ovary cancer
(10%), 1.6-times more frequent prostate cancer (8% of
all and 12% of familial cases), and 1.5-times more fre-
quent breast cancer (7%) [3, 4]. In 4.8% of cases it affects
the Polish population [2, 3]. The frequency of incidence
of this mutation, as well as the variety of cancers to
which it predisposes, makes genetic testing and genet-
ic counselling advisable, especially in patients with pos-
itive familiar history. Genetic supervision should be
implemented in cases where at least two cancers were
diagnosed. In families of carriers of CHEK2 mutations,
DNA testing is necessary.
Description
A woman of 56 years was referred to the Genetic Clinic
due to a positive familial history for monoclonal gam-
mapathy. Her father and her father’s brother and sister
were diagnosed with multiple myeloma. Since 1999 the
patient has been under observation owing to mono-
clonal gammapathy, without treatment. Familial histo-
ry for thyroid diseases is positive: the patient’s mother
and her second sister were diagnosed with nodular
goitres, while her 26-year-old daughter has been treat-
ed with substitutive doses of L-T4 since childhood, due
to hypothyroidism due to Hashimoto’s disease. In ge-
netic testing the patient was diagnosed with CHEK2
mutation (I157T). Oncological diagnostics was conduct-
ed according to the recommendations of the Interna-
tional Centre For Hereditary Cancers at the Department
of Genetics and Pathomorphology of the Pomeranian
Medical University. Thyroid diagnostics indicated
Hashimoto’s disease: TSH — 1.41 uIU/mL (N: 0.4–4.0
uIU/mL), a/TPO — 378 uIU/mL (N: 0–35 uIU/mL).
In thyroid ultrasound there were described in the
right lobe a hypoechogenic solid nodule with micro
calcifications of 10 × 9 mm (P2), in a hypoechogenic
nodule of 10 × 7 mm (P3), and in the left lobe a normo-
echogenic nodule of 25 × 17 mm (L3).
In cytological examination (FNAB) of the thyroid
nodules there were diagnosed: P2 — papillary thyroid
cancer, P3 — nodule of suspicious character, and L3 —
benign tumour. The operation that followed was a to-
tal thyroidectomy. In the histopathological examination
papillary carcinoma was confirmed in the P2 as the
pT3N0Mx tumour. Adjuvant treatment with 131I was
implemented and LT-4 was instituted in a suppressive
dose. Oncology diagnostics for other cancers did not
show any pathologies.
Genetic testing in the patient’s daughter treated for
hypothyroid Hashimoto’s disease found her to be a car-
rier of CHEK2 mutation (I157T), but no presence of can-
cers was found to which this mutation predisposes. The
patient remains under endocrinological observation.
The other family members rejected genetic diagnostics.
Discussion
Human gene CHEK2 encodes CHEK2 protein, a pro-
tein kinase active in DNA-repair. The protein product
regulates the cell response to DNA-damage by phos-
phorylation of a number of cell substrates [1, 2]. The
locus of CHEK2 gene is in the long arm of chromosome
22 (22q12.1). The first identification of CHEK2 was in
budding yeast Saccharomyces cerevisiae as Rad53, and
in Schizosaccharomyces pombe as Cds1 [1]. Both these
proteins were then found to be serine/threonine-kinases
controlling DNA replication and activating inhibition of
the cell cycle as a response to DNA damage. In 2002,
mutation truncating CHEK2 (1100del1C) was first de-
scribed in a patient with breast cancer. In 2003, CHEK2
mutation was proven to be associated with prostate can-
cer. In 2004, mutation of this gene was, for the first time,
revealed to increase the risk of numerous cancers [1–3].
As a response to damage of both strands of DNA,
CHEK2 protein is activated through its dimerisation and
autophosphorylation. Activated CHEK2 starts a num-
ber of cell mechanisms with the result of DNA repair,
inhibition of the cell cycle, or aging and apoptosis of
the cell (Fig. 1).
The mechanism of DNA repair occurs through acti-
vation of BRCA1 by CHEK2 [1, 2, 5, 6]. Phosphorylation
of CDC25C phosphatase causes the inhibition of cell
cycle in the G2 phase [1, 2], and indirect phosphoryla-
tion of CDC25C phosphatase causes inhibition of
S phase [1]. CHEK2 also indirectly regulates inhibition
of the G1 phase of the cell cycle and cell apoptosis acti-
vating phosphorylation of protein p53 [1, 2, 7, 8]. It has
recently been found to be essential for regulating p53
and not for its direct activation [1]. CHEK2 may also
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promote apoptosis through interaction with other cell
substrates. It also influences the process of cell aging.
Telomere damage activates CHEK2, which triggers fur-
ther mechanisms, among others through p53 and p21,
CKD inhibitor in undamaged cells. CHEK2 acts as an
anti-cancer barrier because it induces cancer cell aging,
suppressing their proliferation and, as a result, the pro-
cess of oncogenesis [9].
Illustration 1
Constitutive mutations and polymorphisms in CHEK2
gene are associated with the risk of numerous cancers.
Two main groups of CKEK2 gene mutations have been
described:
— protein truncating mutation:
• 1100delIC,
• IVS2+1G > A,
• Del 5395;
— missense mutations: the most frequent mutation is
I157T, in which on the nucleotide level thymine is
substituted with cytosine at position 433. This chang-
es the reading frame and on the amino acid level
isoleucine at position 157 is substituted with threo-
nine. Missense mutation is located in a functional
domain of CHEK2 gene and the protein which it pro-
duces is defective in recognition and phosphoryla-
tion of CDC25A, protein p53, and BRCA1 [10, 11].
These mutations increase the risk of occurrence of
some cancers [1–3]. Cancer of the prostate and breast
and papillary cancer of the thyroid are associated with
both types of mutations, while cancer of the kidney,
colon, and ovary occur only in the case of I157T muta-
tion [3]. Carriers of kidney cancer present themselves
histopathologically as clear cell carcinoma [3]. Cancers
associated with the most common mutations are pre-
sented in Table I.
In the described case, detecting CHEK2 mutation
(I157T) was incidental. So far in the literature, an asso-
ciation of this mutation with monoclonal gammapathy
has not been described although there are reports of its
association with leukaemia [12]. According to the rec-
ommendations presented below, the patient was
screened for the carcinoma to which this mutation pre-
disposes. Apart from the diagnosed papillary thyroid
carcinoma, no other pathologies were found. Genetic
screening of the family members was positive only in
a daughter with long-standing Hashimoto’s disease,
who was also the mutation carrier. The conducted tests
Figure 1. Schematic overview of the DNA-damage response signalling pathway
Rycina 1. Schemat przedstawiający drogi odpowiedzi komórki na uszkodzenie DNA
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did not find any other pathologies. Both patients will
remain under permanent oncological observation.
In the case of carriers of I157T mutation, no age dif-
ferences were found in developing the carcinoma in
comparison with the cancer-free population [3]. Unlike
these observations, the protein-truncating mutations
demonstrated that the average age of developing can-
cer of the colon and thyroid was lower than in the case
of patients with sporadic cancers [3]. In the case of breast
cancer, the examined women with this carcinoma were
carriers of BRCA1 and CHEK2 I157T. It seems that car-
rying both these mutations does not increase the risk of
breast cancer in comparison with carrying only the
BRCA1 mutation [13]. It was noticed that this mutation
decreased the risk of nicotine-related cancers, includ-
ing lung and nasopharynx [14].
The International Centre for Hereditary Cancers of
Pomeranian Medical University recommends the fol-
lowing screening for the carriers of CHEK2 mutation
I157T [4]:
— for women:
• systematic breast self-control;
• medical breast examination after 40 years of age,
twice a year;
• breast ultrasound after 40 years of age, yearly;
• MRI of breast, or possibly mammography after
40 years of age, once a year alternately with breast
ultrasound;
• vaginal ultrasound of the reproductive organ
after 25 years of age, yearly;
— for men:
• palpation of prostate, PSA after 50 years of age,
yearly;
• prostate saturation biopsy to be considered after
60 years of age, only if, in the family history, rel-
atives of first degree had prostate cancer;
— for both genders:
• abdominal ultrasound after 40 years of age year-
ly, particularly the kidneys;
• colonoscopy or colon contrast enema after
60 years of age, every 5 years or more often,
should any intestinal disorders appear;
• thyroid ultrasound after 20 years of age, yearly.
However, it should be stressed that until now there
are no indications to investigate this germline mutation
in patients with thyroid cancer, when no other cancers
are diagnosed in the proband or in the family.
Conclusions
Missense mutation of CHEK2 (I157T) is related to an
increased predisposition to some cancers, including
a two-fold greater risk of papillary thyroid cancer. It oc-
curs in 4.8% of the Polish population. When the family
history for carcinoma is positive, genetic diagnostics of
the family members is recommended. The presented
family illustrates that haematological malignancies may
also be observed in CHEK2 mutation carriers.
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